PepGen Inc. (PEPG)
| Market Cap | 333.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -96.92M |
| Shares Out | 68.74M |
| EPS (ttm) | -2.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 382,709 |
| Open | 4.650 |
| Previous Close | 4.580 |
| Day's Range | 4.530 - 4.846 |
| 52-Week Range | 0.880 - 9.187 |
| Beta | 1.97 |
| Analysts | Strong Buy |
| Price Target | 8.17 (+68.45%) |
| Earnings Date | Nov 6, 2025 |
About PEPG
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for PEPG stock is "Strong Buy." The 12-month stock price target is $8.17, which is an increase of 68.45% from the latest price.
News
PepGen: DMD Discontinued, Ways To Go With DM1
PepGen Inc. (PEPG) has seen its DM1 trials advance to phase 2 with a great reaction from markets. PEPG discontinued its DMD trials, which explains some of the reduced R&D expenses in the last 3 months...
PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
BOSTON,--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of ...
PepGen Reports Highest Splicing Correction In Dystrophy Patients, Stock Doubles
PepGen Inc. (NASDAQ: PEPG) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro.
PepGen Announces Pricing of $100 Million Public Offering
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of s...
PepGen Announces Proposed Public Offering
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of s...
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of s...
PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options If you suff...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options If you suff...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG
NEW YORK , June 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). Shareholders who purchased shares of PEPG during the class period...
Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein
NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all investors who purchased or otherw...
PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate
PepGen Inc. PEPG announced on Wednesday that it will focus on advancing its myotonic dystrophy type 1 (DM1) program, currently in Phase 2 clinical development.
PepGen to discontinue development of experimental Duchenne therapy; shares drop
Drug developer PepGen said on Wednesday it will discontinue development of its experimental therapy for Duchenne muscular dystrophy (DMD) after it failed to boost production of a protein in a mid-stag...
PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, today announced that based on the levels of dyst...
PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Announces Appointment of Two New Directors to its Board
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls
On Tuesday, PepGen Inc. PEPG announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the company ca...
PepGen to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...